Mast cells play a central role in the pathogenesis of allergic reaction. Activation of mast cells by antigens is strictly dependent on the influx of extracellular calcium that involves a complex interaction between signalling molecules located within the cells. We have previously reported that tHGA, an active compound originally isolated from a local shrub known as Melicope ptelefolia, prevented IgE-mediated mast cell activation and passive systemic anaphylaxis by suppressing the release of interleukin-4 (IL-4) and tumour necrosis factor (TNF)-a from activated rat basophilic leukaemia (RBL)-2H3 cells. However, the mechanism of action (MOA) as well as the molecular target underlying the mast cell stabilising effect of tHGA has not been previously investigated. In this study, DNP-IgE-sensitised RBL-2H3 cells were pre-treated with tHGA before challenged with DNP-BSA. To dissect the MOA of tHGA in IgE-mediated mast cell activation, the effect of tHGA on the transcription of IL-4 and TNF-a mRNA was determined using Real Time-Polymerase Chain Reaction (qPCR) followed by Calcium Influx Assay to confirm the involvement of calcium in the activation of mast cells. The protein lysates were analysed by using Western Blot to determine the effect of tHGA on various important signalling molecules in the LATPLCc-MAPK and PI3K-NFjB pathways. In order to identify the molecular target of tHGA in IgEmediated mast cell activation, the LAT and LAT2 genes in RBL-2H3 cells were knocked-down by using RNA interference to establish a LAT/LAT2 competition model. The results showed that tHGA inhibited the transcription of IL-4 and TNF-a as a result of the suppression of calcium influx in activated RBL-2H3 cells. The results from Western Blot revealed that tHGA primarily inhibited the LAT-PLCc-MAPK pathway with partial inhibition on the PI3K-p65 pathway without affecting Syk. The results from RNAi further demonstrated that tHGA failed to inhibit the release of mediators associated with mast cell degranulation under the LAT/LAT2 competition model in the absence of LAT. Collectively, this study concluded that the molecular target of tHGA could be LAT and may provide a basis for the development of a mast cell stabiliser which targets LAT.
Introduction
Allergy is a hypersensitivity disorder mediated by immunological mechanisms which can cause tissue damage and lifethreatening reactions, including atopic dermatitis, asthma, and anaphylactic shock [1, 2] . One of the key characteristics of allergy is the excessive activation of mast cells by an antigen specific immunoglobulin E (IgE) antibody which results in extreme inflammatory responses [1, 3, 4] . Mast cells are the major effector cells of allergic inflammation, where their roles in innate and adaptive immune responses have been increasingly recognised within the last few years [5] . The binding of antigen-specific IgE to FceRI sensitizes mast cells, enabling them to release mediators in response to subsequent encounter with that specific antigen [3, 4, 6] .
The rat basophilic leukaemia cell line (RBL-2H3), which is known to be a mast cell analogue, has been widely used to determine the signal transduction of FceRI as these cells express abundant FceRI receptors on their cell surfaces [7] [8] [9] . RBL-2H3 cells release preformed and newly synthesised mediators of immune allergic response following crosslinking of IgE-bound FceRI with multivalent allergens [7, [10] [11] [12] . In addition, activated RBL-2H3 cells produce various cytokines, chemokines, prostaglandins and leukotrienes that play important roles in the infiltration of http://dx.doi.org/10.1016/j.bcp.2017.08.010 0006-2952/Ó 2017 Elsevier Inc. All rights reserved.
inflammatory cells and the induction of the late-phase reactions [4, 13] . The effect of these mediators on surrounding cells and tissues is what causes the symptoms and severity of an allergic reaction [6] .
Signalling pathways leading to the degranulation of mast cells after engagement of the IgE on the FceRI receptor have been well studied and extensively characterised [14] [15] [16] . Following FceRI aggregation, a complex series of intracellular signalling processes within mast cells will be initiated [17] . Although the immediate receptor-proximal signalling events seem to be common for the release of all categories of mediators, the receptor-distal signalling events must diverge to regulate the different mechanisms by which these mediators are released [15] . Several lines of evidence have shown that the LAT-PLCc axis as well as the PI3K-NFjB axis pathways play vital roles in coordinating the IgE-dependant mast cell degranulation [15, 18, 19] . Both pathways are activated by a tyrosine kinase known as Spleen tyrosine kinase (Syk) through the phosphorylation of adapter molecules such as linker for activation of T cells (LAT) and Non-T cell activation linker (LAT2) [20] . This will lead to the downstream cascade effects which cause the activation of various key enzymes or molecules along the signalling pathways such as phosphoinositide 3-kinase (PI3K), NFjB p65, phospholipase Cc (PLCc), mitogen-activated protein kinase (MAPK) and arachidonic acid-associated enzymes [14, 15] . Eventually, this will result in the massive influx of Ca 2+ from the surrounding environment into the cell which is considered an important event that triggers mast cell degranulation [20, 21] . As mast cell degranulation has been shown to play an important role in allergic inflammation, coagulation cascades, host defence, and tissue remodelling, increased understanding of mast cell degranulation and the mechanisms involved will lead to the discovery of effective therapy for diseases associated with mast cell degranulation [22] . Until now, the treatment of allergic diseases relies on clinically-prescribed drug classes of mast cell stabilisers or H 1 antagonists such as ketotifen fumarate, olopatadine and cromolyn [6] . These mast cell stabilisers have been reported to attenuate the release of allergic mediators such as histamine, leukotrienes C 4 and PAF, as well as playing a part in the signalling pathway that is associated with Ca 2+ influx inhibition during mast cell activation [23] . For example, cromolyn has been reported to inhibit NF-jB nuclear translocation and the action of phosphorylated MAPK proteins during mast cell activation [24, 25] . At the same time, unwanted side effects such as drowsiness, upset stomach, chest congestion and dry mouth have been associated with the use of these mast cell stabilisers [26] . As such, there are ongoing researches into potential mast cell stabilising agents derived from natural sources, however their mechanisms of action and safety are yet to be established [6] . 2,4,6-Trihydroxy-3-geranylacetophenone (tHGA) is an active compound originated from a local shrub, namely Melicope ptelefolia [27] . It has been traditionally used by locals to treat a wide range of diseases, including itches [28] . Scientific evidence on the antiallergic properties of tHGA has been previously reported where the oral and systemic treatment of tHGA prevented the ovalbumin-induced allergic airway inflammation in a murine model of allergic asthma [29, 30] . Despite the important roles of mast cells as the main immune effector cells involved in the pathogenesis of allergic diseases, there was no report on the mast cell stabilising effect of tHGA until recently, when our research group demonstrated that tHGA inhibited IgE-mediated mast cell degranulation and passive systemic anaphylaxis [31] . However, the mechanism underlying its protective effects is still poorly understood. Therefore, the purpose of this study was to investigate the underlying mechanism of the inhibitory effects of tHGA in a cellular model of IgE-mediated mast cell degranulation.
Material and methods

Compound synthesis and preparation
tHGA, with its chemical structure previously reported [30] , was synthesised according to a previously described method [30] and the stock solution (20 mM) was prepared according to a previous study [31] . Prior to experiments, the activity of several batches of synthetic tHGA was tested in vitro using the b-hexosaminidase release assay. There was minimal variation between different batches of tHGA (<3% variation).
Antibodies and reagents
Mouse anti-dinitrophenol (DNP) monoclonal IgE and 4-Nitrophenyl N-acetyl-b-D-glucosaminide (PNAG) were purchased from Sigma Chemical Co. (St. Louis, MO, USA). DNP-conjugated bovine serum albumin (DNP-BSA) was purchased from Calbiochem (San Diego, CA, USA). The enzyme-linked immunoassay (EIA) kits for histamine, prostaglandins D 2 (PGD 2 ) and leukotrienes C 4 (LTC 4 ) were purchased from Cayman Chemicals (Ann Arbor, MI, USA). The ELISA kits for interleukin 4 (IL-4) and tumour necrosis factor-alpha (TNF-a) were purchased from R&D systems (Minneapolis, MN, USA). Ketotifen fumarate was purchased from MP Biomedicals (Santa Ana, California, USA). Eagle's minimum essential medium (EMEM), foetal bovine serum, penicillin and streptomycin were purchased from Life Technologies Inc. ( 
Cell culture and activation
RBL-2H3 cell line (rat basophilic leukaemia cell line) was purchased from the American Type Culture Collection (ATCC) (Manassas, VA, USA) and cultured in EMEM medium containing 10% foetal bovine serum, 100 U/mL penicillin and 100 mg/mL streptomycin. RBL-2H3 cells were incubated at 37°C in a 5% CO 2 humidified incubator and were subcultured to new T25 tissue culture flask (3 Â 10 5 cells/flask) or used for assays when the confluence of cells reached 80%. Only RBL-2H3 cells of passage number ranging from 6 to 11 were used throughout this study.
Quantitative real-time PCR (qPCR)
To determine the effect of tHGA on the gene expression of IL-4 and TNF-a, RBL-2H3 cells ( 
Western blotting
To determine the effect of tHGA on the signalling molecules in IgE-mediated mast cell activation, RBL-2H3 cells (1 Â 10 7 cells)
were sensitised with 1 mg/mL of DNP-IgE for 24 h. On the next day, the sensitised cells were rinsed with Tyrode's buffer before pre-treatment with tHGA (1.25, 5, 20 mM) for 20 min. The pretreated cells were then challenged with 1 mg/mL of DNP-BSA for 10 min (phospho-Syk, phospho-LAT, phospho-PLCc1, phosphop38, phospho-JNK, phospho-ERK, phospho-PI3K and phosphocPLA 2 ) or 15 min (5-LOX, COX-2, p65, phospho-IKK, phospho-IjB, phospho-cPLA 2 ). At the end of DNP-BSA challenge, the cells were washed with cold PBS, resuspended in lysis buffer (50 mM TrisHCl, pH 8.0, 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 1% protease and phosphatase inhibitors cocktail) and centrifuged to obtain whole cell lysates. For nuclear and cytoplasmic protein extracts, the cells were lysed using the NucBuster TM protein extraction kit according to the manufacturer's protocols with slight modifications. Briefly, the cells were lysed with 300 mL of NucBuster reagent 1 for 5 min on ice. Then, the whole cell lysates were vortexed for 30 s at 8000Âg followed by 10 min of incubation on ice. The same steps were repeated twice. The cell suspension was then centrifuged for 5 min at 16,000Âg and 4°C and the supernatant was stored as a cytosolic fraction. The remaining cell pellet containing nuclei was further lysed with 150 mL of NucBuster reagent 2 containing protease inhibitor cocktail and dithiothreitol (DTT). The cells were vortexed for 30 s at 8000Âg followed by 10 min of incubation on ice. The same steps were repeated thrice. The nuclear debris was then spun down for 5 min at 16,000Âg and 4°C and the supernatant was stored as a nuclear fraction.
The protein samples were separated using 10% (w/v) sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE), transferred onto PVDF membranes, blocked with 5% BSA for 1 h, and subsequently incubated overnight at 4°C with primary antibody (1:1000) specific for 5-LOX, COX-2, Syk, p-Syk, LAT, p-LAT, PLCc1, p-PLCc1, p38, p-p38, JNK, p-JNK, ERK, p-ERK, cPLA 2 , pcPLA 2 , PI3K, p65 NF-jB, IjBa, p-IjBa, IKKa/b, p-IKKa/b in Tris Buffered Saline-Tween (TBST) containing 5% BSA. On the next day, the membranes were incubated for 1 h with goat anti-rabbit IgG secondary antibody (1:5000) diluted in 5% BSA at RT. Finally, the membranes were washed three times in TBST, incubated with chemiluminescent substrate solution for 1 min, and visualised using the Fusion FX gel documentation system (Vilber Lourmat, Eberhardzell, Germany).
Kinase assay
To determine the effect of tHGA on Syk kinase activity, a Syk kinase enzyme system assay kit was used according to the manufacturer's protocols. Briefly, 25 lL of kinase reaction (50 ng Syk kinase, 10 mM ATP and 2 mg Poly E 4 Y 1 ) containing tHGA (5 or 20 mM) in 1X kinase buffer was added to the wells of a 96-well solid white plate and incubated for 60 min at RT. Then, 25 lL of ADP-Glo TM reagent was added to the kinase reaction followed by further incubation of the plate for 40 min at RT. Finally, the plate was treated with 50 lL of kinase detection reagent and incubated for 30 min at RT, before the plate was taken to measure the luminescence signal using a Panomics luminometer (Santa Clara, CA, USA). 
Analysis of histamine release
To determine the effect of tHGA on the release of preformed mediators in LAT-deficient RBL-2H3 cells, the release of histamine upon treatment with tHGA was examined. LAT-deficient RBL-2H3 cells were sensitised with 1 mg/mL of DNP-IgE for 24 h. On the next day, the sensitised cells were washed with Tyrode's buffer before pre-treatment with tHGA (5 and 20 mM) for 20 min. The pretreated cells were then challenged with 1 mg/mL of DNP-BSA for 1 h. At the end of DNP-BSA challenge, the culture supernatant was centrifuged (17,000Âg, 10 min) at 4°C. The level of histamine in the culture supernatant was measured by using a Histamine EIA kit according to the manufacturer's instructions. The same protocol was also applied to determine the release of histamine in LAT/ LAT2-deficient RBL-2H3 cells.
Analysis of TNF-a, IL-4, PGD 2 and LTC 4
To determine the effect of tHGA on the release of de novo mediators in LAT-deficient RBL-2H3 cells, the cells (2 Â 10 5 cells/well)
were sensitised with 1 mg/mL of DNP-IgE for 24 h. On the next day, the sensitised cells were rinsed with Tyrode's buffer before pre-treatment with tHGA (5 and 20 mM) for 20 min. The pretreated cells were then challenged with 1 mg/mL of DNP-BSA for 6 h. At the end of DNP-BSA challenge, the culture supernatant was centrifuged (17,000g, 10 min) at 4°C. The levels of PGD 2 and LTC 4 were measured by using PGD 2 and LTC 4 EIA kits, whereas the levels of IL-4 and TNF-a were measured by using IL-4 and TNF-a ELISA assay kits according to the manufacturer's instructions. The same protocol was also applied to determine the release of de novo mediators in LAT/LAT2-deficient RBL-2H3 cells.
Statistical Analysis
All experiments described were performed three times. The results were expressed as means ± S.E.M. Statistical analyses were performed using SPSS 19.0 (Chicago, IL, USA). One-way analysis of variance (ANOVA) followed by Tukey's test was used to compare the results from different treatment groups. P values of less than 0.05 were considered as statistically significant.
Results
tHGA inhibits IL-4 and TNF-a mRNA expression in IgE-antigen complex-stimulated RBL-2H3 cells
Our previous study demonstrated that tHGA was able to inhibit mast cell degranulation through the attenuation of mediator release, including IL-4 and TNF-a from IgE-antigen complexstimulated RBL-2H3 cells [31] . In order to understand the mechanism of action of tHGA on IgE-antigen complex-stimulated RBL-2H3 cells, we continued to determine the effect of tHGA on the gene expression of IL-4 and TNF-a using Real Time-PCR. As shown in Fig. 1A and B, DNP-BSA challenge for 6 h significantly increased the mRNA levels of IL-4 and TNF-a in IgE-antigen complexstimulated cells by approximately 16.7-and 20.6-fold, respectively. On the other hand, at 5 and 20 mM, tHGA significantly and concentration-dependently reduced the mRNA levels of IL-4 and TNF-a by approximately 26-50% in comparison to the IgEantigen complex-stimulated cells. However, tHGA failed to significantly decrease the mRNA levels of both IL-4 and TNF-a at the concentration of 1.25 mM. 
tHGA inhibits the phosphorylation of LAT-PLCc pathway in IgEantigen complex-stimulated RBL-2H3 cells
It is well known that the increase in intracellular Ca 2+ influx will cause activation of the LAT-PLCc pathway in IgE-antigen complexstimulated RBL-2H3 cells [5] . Fig. 2A and B show that DNP-BSA significantly up-regulated the phosphorylation of PLCc and LAT in IgE-antigen complex-stimulated RBL-2H3 cells by approximately 6.7-fold. On the other hand, pre-treatment with 5 and 20 mM tHGA significantly attenuated the phosphorylation of these two signalling proteins by approximately 23-45%. However, tHGA at the concentration of 1.25 mM was too low to cause a significant reduction on the phosphorylation of both PLCc and LAT in comparison to the IgE-antigen complex-stimulated RBL-2H3 cells.
3.4. tHGA inhibits the phosphorylation of cPLA 2 and enzymes associated with the arachidonate cascade pathway in IgE-antigen complex-stimulated RBL-2H3 cells
Our previous study reported that tHGA inhibited the release of PGD 2 and LTC 4 in IgE-mediated mast cell degranulation [31] whereby the production of PGD 2 and LTC 4 is mediated by the arachidonate cascade pathway and involves enzymes such as cPLA 2 , 5-LO and COX-2 [33, 34] . Fig. 3A to C shows that DNP-BSA significantly induced the phosphorylation of cPLA 2 as well as the levels of both 5-LO and COX-2 proteins in IgE-antigen complexstimulated cells by approximately 6.2-to 6.6-fold. However, these adverse effects were significantly reduced in a concentrationdependent manner in the presence of tHGA. Pre-treatment with 5 and 20 mM tHGA significantly reduced the phosphorylation of cPLA 2 by approximately 23.9% and 41.4%, respectively, in comparison to the IgE-antigen complex-stimulated cells. Furthermore, the expression levels of both 5-LO and COX-2 were also reduced by approximately 17-24% (5 mM tHGA) and 24-48% (20 mM tHGA) with respect to the IgE-antigen complex-stimulated RBL-2H3 cells. Conversely, at the concentration of 1.25 mM, tHGA failed to downregulate the levels of all of the enzymes associated with the arachidonate cascade pathway.
tHGA inhibits the activation of MAPK proteins in IgE-antigen complex-stimulated RBL-2H3 cells
The activated LAT-PLCc pathway in IgE-antigen complex stimulated RBL-2H3 cells is reported to be associated with the activation of MAPK proteins including ERK 1/2, p38 and JNK [33, 34] . to the IgE-antigen complex-stimulated cells. Apparently, consistent with other results so far, 1.25 mM of tHGA failed to inhibit the phosphorylation of all of the MAPK proteins.
tHGA partially inhibits activation of the PI3K-NFjB pathway in IgE-antigen complex-stimulated RBL-2H3 cells
Previous reports demonstrated crosstalk between the LAT-PLCc pathway and the PI3K-NFjB pathway through MAPK proteins, which collectively leads to the production of cytokines from IgEantigen complex-stimulated mast cells [33, 35] . In the present study, Fig. 4A to D demonstrated that DNP-BSA significantly induced, by approximately 5.0-to 8.7-fold, the expression of PI3K, phosphorylated IKKa/b and phosphorylated IjBa, as well as the translocation of p65 into the cell nucleus of IgE-antigen complex-stimulated cells. However, in the presence of 20 mM tHGA, the phosphorylation of IjBa and nuclear translocation of NFjB p65 were significantly reduced by 13.2% and 13.7%, respectively. There was no inhibition of these two signalling proteins in IgE-sensitised RBL cells pre-treated with 1.25 and 5 mM of tHGA. Interestingly, the inhibitory effect of tHGA was not significant, even at 20 mM, on the expression of PI3K and phosphorylation of IKK, which are located upstream of IjBa and NFjB p65.
3.7. tHGA does not inhibit the phosphorylation of Syk and its kinase activity in IgE-antigen complex-stimulated RBL-2H3 cells
As Syk is the upstream molecule of both LAT-PLCc and PI3K-NFjB pathways, the significant role of Syk, especially in IgEdependent mast cell activation, has been previously shown by various studies [36, 37] . According to Fig. 5A , DNP-BSA significantly induced the phosphorylation of Syk in IgE-antigen complexstimulated cells by approximately 6.6-fold. Surprisingly, the presence of tHGA was not able to reduce the phosphorylation of Syk. In order to exclude the possibility that tHGA might inhibit Syk kinase activity without inhibiting its phosphorylation, the effect of tHGA on Syk kinase activity was examined and negative results were obtained. None of the three concentrations of tHGA used (1.25, 5 and 20 mM) were able to show any inhibitory effect on Syk kinase activity (Fig. 5B) . Nonetheless, ketotifen fumarate, which served as the drug control in this study, was able to significantly reduce the Syk kinase activity by approximately 22% without affecting Syk phosphorylation.
3.8. The effects of LAT, LAT2, and LAT/LAT2 deficiency on the release of mediators from IgE-antigen complex-stimulated RBL-2H3 cells Thus far, the results in this present study have shown that tHGA does not inhibit the upstream signalling of the PI3K-NFjB pathway. At the same time, the inhibitory effect of tHGA on the LATPLCc-MAPK axis pathway stops at LAT without further interfering the phosphorylation and kinase activity of its upstream molecule, Syk. Collectively, all these findings indicated that LAT could be the molecular target of tHGA in IgE-mediated mast cell degranulation. In order to confirm whether LAT is the molecular target of tHGA in this study, cellular models of LAT, LAT2 and LAT/LAT2 gene knockdown were developed by using transient transfection.
The efficacy of siRNA-mediated down-regulation of LAT, LAT2 and LAT/LAT2 protein expressions were examined by performing Western Blot. Two siRNA (siRNA1 and siRNA2) were used to knock down the expression of both LAT and LAT2. As shown in Fig. 6A , after 24 h of transfection, siRNA1 and siRNA2 significantly downregulated the protein expression of LAT by 70.1% and 71.9% respectively. When the transfection period was prolonged to 48 h, the protein expressions of LAT by cells transfected by siRNA1 and siRNA2 were down-regulated by approximately 70.3% and 70.5% respectively. Similarly, Fig. 6B shows that the proteins expressions of LAT2 were significantly down regulated by siRNA1 and siRNA2 by 72.7% and 73.3% respectively after 24 h of transfection. The efficacy did not increase significantly when the cells were transfected with siRNA1 and siRNA2 of LAT2 up to 48 h. As the efficacy of all siRNA used to down-regulate LAT and LAT2 protein expressions were similar, siRNA1 of LAT and LAT2 were selected to knock down the protein expressions of LAT and LAT2 simultaneously. Fig. 6C shows that the proteins expressions of both LAT and LAT2 were significantly down regulated by approximately 70.3% and 71.8% respectively, after 24 h of siRNAs' transfection. Consistent with the earlier findings in Fig. 6A and 6B, the efficacy of siRNAmediated down-regulation of LAT and LAT2 did not increase significantly after 48 h of transfection. Hence, subsequent experiments in this study were conducted by transfecting the cells with siRNA for 24 h. For the positive control, the protein expressions of GAPDH in all the experiments were being down regulated consistently by approximately 88.7-90.1% when compared to the normal cells. In order to confirm that these siRNAs specifically silence the LAT and LAT2 genes without interfering the phosphorylation of upstream signalling molecules, the phosphorylation level of Syk was also examined in these siRNAs treated RBL-2H3 cells. The Western Blot results confirmed that the silencing of both or either one of the adapter protein did not affect the upstream signalling event of IgE-mediated mast cell activation (data not shown).
The effects of silencing LAT, LAT2 and LAT/LAT2 in IgE-antigen complex-stimulated RBL-2H3 cells were determined by measuring the release of histamine, which is a preformed mediator released during the early stage of mast cell activation [38] . According to Fig. 7A , under normal condition, histamine release was significantly increased by 21.3-fold following 1 h of DNP-BSA incubation in challenged cells compared to normal cells. However, LAT deficiency alone or both LAT/LAT2 deficiency led to only 14.1 and 6.2-fold increase respectively. This indicates that histamine release in LAT or LAT/LAT2 deficient challenged cells was suppressed respectively by 34% and 71% compared to challenged cells. By contrast, LAT2 deficiency alone led to 27.6-fold increase, indicating that histamine release by LAT2-deficient challenged cells was greater by 30% compared to challenged cells.
Apart from the release of preformed mediators in the early phase of mast cell degranulation, prolonged exposure of IgEantigen complex-stimulated RBL-2H3 cells to antigen results in the late phase reaction and production of de novo inflammatory mediators including PGD 2 , LTC4, IL-4 and TNF-a [39, 40] . As shown in Fig. 7B to 7E , under normal condition, PGD 2 , LTC4, IL-4 and TNFa release were significantly increased by approximately 13-to 21-fold following 6 h of DNP-BSA incubation in challenged cells compared to normal cells. However, LAT deficiency alone or both LAT/ LAT2 deficiency led to only 9-to 13-fold and 4-to 6-fold increase respectively. This indicates that the de novo mediators' release in LAT or LAT/LAT2 deficient challenged cells was suppressed respectively by 33-46% and 71-75% compared to challenged cells. In contrast, LAT2-deficient challenged cells demonstrated an increase in the release of de novo mediators by approximately 16-to 28-fold in comparison to normal cells, which was 22-35% higher than challenged cells.
tHGA does not inhibit the release of key mediators associated with mast cell degranulation by LAT-deficient IgE-antigen complexstimulated RBL-2H3 cells
In order to confirm that tHGA inhibits mast cell activation by specifically targeting LAT, the ability of tHGA to inhibit the release of key mediators associated with mast cell degranulation in LATdeficient challenged cells were examined. Consistent with the results from Fig. 7 , one hour of DNP-BSA challenge significantly Fig. 4 . The effects of tHGA on the expression levels of (A) p-IjB, (B) IjB, (C) nuclear p65, (D) cytosolic p65, (E) IKK a/b, and (F) PI3K in IgE-antigen complex-stimulated RBL-2H3 cells. IgE-sensitised RBL-2H3 cells were pre-treated with tHGA (1.25, 5 and 20 lM) for 20 min, and followed by DNP-BSA challenge (1 mg/mL) for 30 min. Whole cell protein extracts were assayed by using Western Blot to determine the expression levels of p-IjB, IjB, IKK a/b, and PI3K. Nuclear and cytosolic fraction was used to determine the levels of nuclear p65 and cytosolic p65 respectively. The phosphorylated forms IKK a/b were normalised with its native proteins in the experiment. The internal control used for p-IjB, IjB, cytosolic p65 and PI3K was b-actin whereas for nuclear p65 was TFIIB. Results are expressed as the mean ± S.E.M values of three independent experiments. *** P < 0.005, 
Discussion
tHGA, a geranyl acetophenone and also a phloroglucinol compound, has been previously reported to contain mast cell stabilising properties by preserving the mast cell structure and attenuating the release of pro-inflammatory mediators in the in vitro model of IgE-mediated mast cell degranulation as well as in an animal model of systemic anaphylaxis [31] . Allergic diseases have been considered to be highly associated with mast cell activation and the release of various inflammatory mediators such as histamine, PGD 2 , LTC 4 , IL-4 and TNF-a. Over the years, therapeutic approaches in allergic medicine attempt to target mast cell activation as well as the release of mediators associated with mast cell activation [20, 41] ; for example, ketotifen fumarate, one of the second-generation antihistamine drugs which is widely used to ameliorate many allergic disorders in individuals such as allergic conjunctivitis and chronic rhinitis by suppressing many proinflammatory signalling pathways [42] [43] [44] . Studies reported that ketotifen fumarate inhibits the phosphorylation of various important signalling molecules during mast cell activation such as Syk, MAPKs, PI3K and NFjB [6, 25, 45, 46] . However, the use of such drugs on allergic patients is always associated with unwanted effects such as irritation, headache, runny nose, increased sensitivity to light and even a decrease in drug tolerability [26] .
Recent studies and development have been heading towards the discovery of substances isolated from natural sources as the next generation mast cell stabilisers [6] ; it is important to understand the mechanism of action (MOA) of these substances before they can be safely entered into clinical trials. Our research group has previously reported that tHGA is able to prevent mast cell degranulation and attenuate the release of preformed mediators such as histamine and the synthesis of de novo pro-inflammatory cytokines such as IL-4 and TNF-a. However, the underlying mechanism by which tHGA exerts its mast cell stabilising effects is currently unclear. The present study dissected the underlying mechanisms by determining whether tHGA inhibits the mRNA expression of IL-4 and TNF-a. Upon confirmation of that, the two major signalling pathways in IgE-mediated mast cell activation, the LAT-PLCc-MAPK and PI3K-NFjB pathways, were studied. Lastly, the possible molecular targets located along the LATPLCc-MAPK or PI3K-NFjB pathways in IgE-mediated mast cell degranulation.
In line with the ELISA results in our previous study, which demonstrated the inhibitory effect of tHGA on the release of IL-4 and TNF-a in IgE-mediated mast cell degranulation [31] , the results from real-time PCR show that tHGA inhibited the mRNA expression of IL-4 and TNF-a. This finding has proven that tHGA inhibits the synthesis of IL-4 and TNF-a in IgE-mediated mast cell degranulation, not only at the cellular level but also at the gene transcriptional level. As the transcriptional process of IL-4 and TNF-a genes is regulated by the transcription factors and signalling molecules along the major signalling pathways in IgE-mediated mast cell activation, such as the LAT-PLCc-MAPK and PI3K-NFjB pathways [15] , we continued the study by examining the effect of tHGA on the signalling molecules involved in LAT-PLCc-MAPK and PI3K-NFjB pathways.
Previous studies have demonstrated that Ca 2+ is highly associated with the LAT-PLCc-MAPK pathway in mast cell degranulation [15, 16] . An increase in intracellular Ca 2+ , as a result of massive entry from the extracellular surrounding, is necessary for the activation of various transcription factors which are crucial for the transcription of many cytokine genes including IL-4, TNF-a, and IL-13 [47] . The results show that tHGA was able to attenuate the level of intracellular Ca 2+ in IgE-antigen complex-stimulated mast cells.
This finding also indicates that Ca 2+ flux, which is one of the hallmarks in response to FceRI aggregation, is an unequivocal essential feature of the inhibitory effect of tHGA in IgE-mediated mast cell activation. As LAT and PLCc are the two signalling molecules which cause the influx of Ca 2+ in an activated mast cell [48] [49] [50] , we continued to study the effect of tHGA on LAT and PLCc by using Western Blot. The results show that 20 lM of tHGA inhibited the phosphorylation of both LAT and PLCc by as much as 50%, with the inhibitory effect comparable to 300 lM of ketotifen fumarate, which is a clinically used mast cell stabiliser in allergic reactions. This finding once again confirmed that tHGA exerts its mast cellstabilising effect primarily via the LAT-PLCc pathway. Interestingly, while tHGA inhibited the activation of most signalling molecules involved in the LAT-PLCc pathway, including LAT, PLCc and Ca 2+ influx, it did not inhibit the phosphorylation of Syk. Syk is located upstream of LAT and PLCc and is responsible for activation of the LAT-PLCc pathway. As Syk is a tyrosine kinase, the effect of tHGA on Syk kinase activity was studied by performing a kinase assay before Syk was ruled out as the possible molecular target of tHGA. This finding is interesting as Syk has been known as the common molecular target for most of the mast cell stabilisers, including ketotifen fumarate. Our results show that ketotifen fumarate significantly inhibited the kinase activity of Syk without inhibiting its phosphorylation, which is consistent with previous studies [46, 51] . Activated Syk phosphorylates a variety of substrates including LAT, which orchestrates downstream signalling resulting in degranulation and cytokine gene transcription [6] . However, mast cell stabilisers with Syk as the molecular target could be associated with unwanted side effects as Syk is required for the development and function of various tissues. Syk À/À mice have also been reported to have high rates of perinatal lethality, and exhibit cardiovascular, immune, and hematopoietic defects [36] . After confirming that tHGA did not inhibit both phosphorylation and kinase activity of Syk, we speculate that tHGA may be able to inhibit other signalling cascades that are related to the LAT axis pathway, such as the LAT-MAPK pathway [17, 48] . The present study demonstrates that tHGA attenuated the phosphorylation of all MAPK enzymes including ERK1/2, JNK, and p38. This is expected because we have demonstrated earlier that tHGA inhibited LAT activation. Since LAT is known to positively regulate MAPKs activation, tHGA's inhibitory effect on LAT activation subsequently attenuated MAPK activation. MAPKs have been shown to mediate the activation of several enzymes associated with arachidonic acid, including cPLA 2 , 5-LOX and COX-2 [15, 33] . These enzymes are important for the production of key mediators such as LTC 4 and PGD 2 in IgE-mediated mast cell degranulation [33, 52] . As expected, tHGA inhibited the phosphorylation of cPLA 2 and downregulated 5-LOX and COX-2 protein expression, effects which are likely attributed to the inhibitory effect of tHGA on MAPKs activation. These findings explain the mechanisms underlying tHGA's inhibitory effect on the release of PGD 2 , LTC 4 , IL-4 and TNF-a in IgEmediated mast cell degranulation as reported in our previous study [31] .
Thus far, we have demonstrated that tHGA exerts its mast cellstabilising effect via the LAT-PLCc pathway without affecting Syk. The inhibitory effect of LAT-PLCc pathway was further confirmed by the evidence that tHGA inhibited the phosphorylation of MAPKs, which play vital roles in the LAT axis signalling pathway. However, it is still questionable whether tHGA also exerts its mast cell stabilising effect via another major pathway in IgE-mediated mast cell activation, the PI3K-NFjB pathway. PI3K and NFjB are both important signalling molecules in mast cell biology. Both of these molecules, together with the adapter protein LAT2, are responsible for forming the complementary activation pathway which can also govern the release of mediators in IgE-mediated mast cell degranulation [15] . The results from this complementary pathway show that only 20 lM of tHGA was able to subtly inhibit ($13%) the phosphorylation of IjBa and nuclear translocation of NFjB p65 in IgE-antigen complex-stimulated mast cells. However, tHGA did not show any inhibitory effect on the phosphorylation of IjB kinase (IKK) and PI3K along the PI3K-NFjB pathway. Notably, the inhibitory effects of tHGA on IjB and NFjB were not as strong as those of signalling molecules located in the LAT axis pathway. The partial inhibitory effect of tHGA on the PI3K-NFjB pathway can be explained by several recent studies which reported about the presence of crosstalk between the LAT-MAPK and PI3K-NFjB signalling pathways, specifically in between MAPKs and NFjB p65 [33, 53] . This may explain why tHGA inhibited NFjB p65 and IjBa as well as their downstream molecules, but not the signalling molecules located upstream of NFjB p65 and IjBa. Up to this point, our results strongly demonstrate that tHGA primarily exerts its mast cell-stabilising effect via the LAT-PLCc pathway. Although tHGA also inhibited some of the signalling molecules from the PI3K-NFjB pathway, it could have resulted from the crosstalk between MAPKs and NFjB. Collectively, our findings indicate that it is highly probable that tHGA exerts its mast cell-stabilising effect in IgE-mediated mast cell degranulation by targeting the adapter molecule LAT.
In order to confirm that LAT is the molecular target of tHGA in IgE-mediated mast cell degranulation, the RNAi method was performed to establish LAT, LAT2 and LAT/LAT2-deficient RBL-2H3 cells. The rationale for the use of LAT or LAT2 knockdown strategy in this study is, the competition between LAT and LAT2 which eventually lead to the release of mediators in the event of mast cell activation allows the identification of the molecular target of tHGA by examining the release of mediators when LAT or LAT2 gene is silenced. For example, if the molecular target of tHGA is LAT, tHGA pretreatment will not affect the release of mediators when only the LAT gene is silenced. Interestingly, silencing LAT gene will not impede the cells from undergoing mast cell activation and release all the relevant mediators as LAT2 will take over the dominant role of LAT when the expression of LAT is low. On the other hand, if tHGA targets signalling molecules other than LAT, the release of mediators will be inhibited when the challenged cells are pretreated with tHGA. When this happens, it is important to confirm whether tHGA also targets LAT2 as LAT2 is a homolog to LAT. Therefore, in order to determine the molecular target of tHGA in an IgE-mediated mast cell activation model, it is extremely important to establish the LAT/LAT2 competition model. The relationship and interaction between LAT and LAT2 has been suggested by Orr and McVicar (2010) [54] , by using RNA interference (RNAi) method in primary cells such as bone marrow mast cells and human mast cells [55] [56] [57] . However, this is the first time that LAT/LAT2 competition model was demonstrated in RBL-2H3 cells.
LAT and LAT2 are both important adaptor molecules that can be found on the lipid raft of mast cells [58] . These adaptor molecules are substrates of the tyrosine kinase Syk following their engagement by an activated FceRI receptor. The main function of LAT and LAT2 is to serve as a scaffold protein for the recruitment of other signalling molecules such as PI3K and PLCc in order to propagate down the activation signal [58, 59] . Previous studies have demonstrated that antigen-mediated degranulation, Ca 2+ mobilisation, cytokine production and the activation of signalling molecules such as MAPKs and PLCc were all inhibited partially in LAT À/À mast cells, further decreased in LAT
and surprisingly, increased in LAT2 À/À mast cells [55] [56] [57] . Therefore, the effects of tHGA on the release of mediators from LAT, LAT2 and LAT/LAT2-deficient RBL-2H3 cells will be utilised in this study to determine whether LAT is the specific molecular target of tHGA in IgE-antigen complex-stimulated RBL-2H3 cells. Consistent with previous studies [56, 57] , similar trend was observed in challenged cells following knockdown of either LAT or LAT2 alone or both, whereby the release of mediators was partially decreased in LAT-deficient challenged cells, further decreased in LAT/LAT2-deficient challenged cells and finally increased in LAT2-deficient challenged cells. According to the LAT/LAT2 competitive model proposed by Orr and McVicar (2010) , the competition between LAT and LAT2 in the localisation to lipid rafts and the availability of binding proteins may account for such observations [54] . Therefore, the LAT2, through its complementary PI3K-NFjB signalling cascade, acts as a negative regulator of LAT signalling in wild type (WT) mast cells but may also deliver weaker degranulation signals when expressed in LAT-deficient mast cells [56, 57, 60] (Fig. 9) .
Once the validity of the LAT/LAT2 competitive model was demonstrated in IgE-antigen complex-stimulated RBL-2H3 cells, the LAT-deficient challenged RBL-2H3 cells were then pre-treated with tHGA to observe the release of key mediators in IgEmediated mast cell activation. It is hypothesised that there will not be significant decrease in the release of mediators by the challenged cells in the deficiency of LAT if tHGA specifically targets LAT without interfering with LAT2 or other signalling molecules associated with mast cell activation. Interestingly, the results show that the release of key mediators such as IL-4, TNF-a, PGD 2 and LTC 4 were not affected by tHGA in LAT-deficient challenged cells. Several studies have suggested that, when LAT is being lowly expressed in a mast cell, LAT2 will take over the dominant role of LAT in regulating the release of mediators in the event of mast cell activation [54] [55] [56] . This may explain the inability of tHGA pre-treatment to decrease the release of mediators in LATdeficient challenged cells despite the fact that there were approximately 30% of LAT remaining in the cells.
Such results confirmed that tHGA indeed exerts its mast cell stabilising effect via the LAT-PLCc pathway, with LAT as the possible molecular target. Up to this point, it is important to address the following two questions: (i) does tHGA inhibit the expression of LAT? or (ii) does tHGA influence the adaptor function of LAT? We excluded the possibilities that tHGA could inhibit the expression of LAT or LAT2, as demonstrated by our results (data not shown). Thus, we strongly believe that tHGA exerts it mast cell stabilising effect by affecting the adaptor function of LAT. LAT is an adaptor protein which plays a critical role in FceRI-mediated signalling in mast cells by acting as a signalling hub for the binding of various important downstream messenger proteins such as PLCc [61, 62] . It is possible that tHGA may interfere with the phosphorylation site of the LAT residues, resulting in the destabilisation and deformation of the LAT-based signalling complexes that causes the attenuation of mast cell activation [61] . However, due to difficulty in crystallising the membrane proteins, the complete crystallised structure of LAT is still unknown [60] . Therefore, it remains a question on how tHGA acts upon LAT to cause a loss of function. More in-depth studies should be carried out before any decisive conclusion can be drawn. At this current stage, it can only be concluded that LAT is important in the mast cell stabilising effect of tHGA.
To the best of our knowledge, there is currently no compound or small molecule that attenuates IgE-mediated mast cell degranulation through the specific inhibition of LAT. Many of the pharmacological studies reported compounds which target other signalling molecules such as Syk and PI3K [63] [64] [65] , or soluble mediators such as histamine, lipid mediators, cytokines and chemokines [66, 67] . However, as discussed earlier, there are some drawbacks and side effects associated with these compounds. Apart from that, wide range selectivity of current drug treatment in allergy increases potential side effects and adverse drug reactions [66] . In comparison to Syk which is required for the development and function of various tissues, LAT is central to FceRI-mediated signalling and effector function in mast cells, while not having any obvious role in mast cell development [68] . This suggests that inhibiting IgEmediated mast cell degranulation through LAT might be one of the potential options for drug treatment in the future. However, whether tHGA might target other cell types such as basophils or T cells is still a mystery and should be addressed in the future.
In summary, the present study demonstrated that tHGA attenuated IgE-antigen complex-stimulated RBL-2H3 degranulation primarily via the LAT-PLCc pathway. The inhibition of LAT enables tHGA to partially inhibit the PI3K-NFjB pathway via the crosstalk between MAPK and NFjB, resulting in an overall attenuation of the IgE-mediated mast cell activation (Fig. 10) . This study also validated the LAT/LAT2 competitive model in IgE-antigen complexstimulated RBL-2H3 cells via the establishment of LAT, LAT2 and LAT/LAT2-deficient RBL-2H3 cells. The LAT/LAT2 competitive model successfully proved that the possible molecular target of tHGA in IgE-mediated mast cell degranulation could be LAT. However, more studies should be conducted in the future to fully understand the interaction between tHGA and LAT in attenuating IgE-mediated mast cell degranulation. 4 . Activated Syk also regulates the PI3K pathway through the adaptor protein LAT2, which plays a key role in NFjB-mediated expression of COX-2 and mRNA generation for the pro-inflammatory cytokines.
